Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACBFF NASDAQ:MRUS OTCMKTS:TRUU OTCMKTS:ZLDPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACBFFAurora Cannabis$5.05+4.3%$4.80$2.20▼$12.53$4.85BN/A4.22 million shs932,988 shsMRUSMerus$67.13-2.1%$63.18$33.19▼$69.20$5.08B1.19847,178 shs391,593 shsTRUUTrue Drinks$0.31+5.9%$0.15$0.00▼$0.08$1.56B10.91.01 million shs409,087 shsZLDPFZealand Pharma A/S$65.74-8.0%$59.68$49.98▼$136.76$4.67B0.73891 shs110 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACBFFAurora Cannabis-1.43%-10.70%+8.04%-18.66%-10.54%MRUSMerus+2.02%+3.39%+7.11%+24.52%+36.72%TRUUTrue Drinks+4.21%+11.55%+114.75%+188.88%+230.00%ZLDPFZealand Pharma A/S0.00%+2.86%+42.58%-3.56%-42.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACBFFAurora Cannabis$5.05+4.3%$4.80$2.20▼$12.53$4.85BN/A4.22 million shs932,988 shsMRUSMerus$67.13-2.1%$63.18$33.19▼$69.20$5.08B1.19847,178 shs391,593 shsTRUUTrue Drinks$0.31+5.9%$0.15$0.00▼$0.08$1.56B10.91.01 million shs409,087 shsZLDPFZealand Pharma A/S$65.74-8.0%$59.68$49.98▼$136.76$4.67B0.73891 shs110 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACBFFAurora Cannabis-1.43%-10.70%+8.04%-18.66%-10.54%MRUSMerus+2.02%+3.39%+7.11%+24.52%+36.72%TRUUTrue Drinks+4.21%+11.55%+114.75%+188.88%+230.00%ZLDPFZealand Pharma A/S0.00%+2.86%+42.58%-3.56%-42.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACBFFAurora Cannabis 0.00N/AN/AN/AMRUSMerus 3.08Buy$88.7532.21% UpsideTRUUTrue Drinks 0.00N/AN/AN/AZLDPFZealand Pharma A/S 3.43BuyN/AN/ACurrent Analyst Ratings BreakdownLatest TRUU, ACBFF, MRUS, and ZLDPF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025MRUSMerusIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.008/25/2025MRUSMerusAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.008/15/2025ZLDPFZealand Pharma A/SZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/6/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$97.00 ➝ $96.007/24/2025ZLDPFZealand Pharma A/SWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/7/2025ZLDPFZealand Pharma A/SBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/1/2025ZLDPFZealand Pharma A/SBNP ParibasSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACBFFAurora CannabisN/AN/AN/AN/AN/AN/AMRUSMerus$36.13M140.52N/AN/A$9.46 per share7.10TRUUTrue Drinks$1.95M801.85N/AN/A($0.03) per share-10.48ZLDPFZealand Pharma A/S$9.09M513.61N/AN/A$17.59 per share3.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACBFFAurora CannabisN/A$0.1242.08∞N/AN/AN/AN/AN/AMRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)TRUUTrue Drinks-$3.88M$0.0131.44∞N/A-255.80%N/A-165.86%N/AZLDPFZealand Pharma A/S-$156.43M$14.244.62N/AN/A73.90%82.30%75.17%11/6/2025 (Estimated)Latest TRUU, ACBFF, MRUS, and ZLDPF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ZLDPFZealand Pharma A/S$16.72$16.06-$0.66$16.06$9.18 billion$1.43 billion8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACBFFAurora CannabisN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ATRUUTrue DrinksN/AN/AN/AN/AN/AZLDPFZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACBFFAurora CannabisN/AN/AN/AMRUSMerusN/A8.398.39TRUUTrue DrinksN/A0.01N/AZLDPFZealand Pharma A/S0.0325.1025.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACBFFAurora CannabisN/AMRUSMerus96.14%TRUUTrue DrinksN/AZLDPFZealand Pharma A/SN/AInsider OwnershipCompanyInsider OwnershipACBFFAurora CannabisN/AMRUSMerus3.70%TRUUTrue Drinks18.18%ZLDPFZealand Pharma A/SN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACBFFAurora Cannabis1,340960.96 millionN/ANot OptionableMRUSMerus3775.63 million72.84 millionOptionableTRUUTrue Drinks404.97 billionN/ANot OptionableZLDPFZealand Pharma A/S34071.02 millionN/ANot OptionableTRUU, ACBFF, MRUS, and ZLDPF HeadlinesRecent News About These CompaniesICON Plc and Zealand Pharma’s Petrelintide Study: A Key Update for InvestorsSeptember 7 at 7:18 PM | msn.comZealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Still a Buy?September 5, 2025 | marketbeat.comZealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - What's Next?August 27, 2025 | marketbeat.comDeutsche Bank Remains a Hold on Zealand Pharma (ZLDPF)August 25, 2025 | theglobeandmail.comZealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Drop in Short InterestAugust 22, 2025 | marketbeat.comZealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Rating of "Buy" by AnalystsAugust 21, 2025 | marketbeat.comWilliam Blair Estimates OTCMKTS:ZLDPF Q3 EarningsAugust 19, 2025 | marketbeat.comZealand Pharma A/S (OTCMKTS:ZLDPF) Trading Up 4.3% - Still a Buy?August 17, 2025 | marketbeat.comOTCMKTS:ZLDPF FY2027 EPS Estimate Increased by William BlairAugust 17, 2025 | marketbeat.comZealand Pharma A/S (OTCMKTS:ZLDPF) Issues Quarterly Earnings ResultsAugust 16, 2025 | marketbeat.comZealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Here's WhyAugust 14, 2025 | marketbeat.comZealand Pharma A/S (ZLDPF) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comZealand CEO: Oral weight loss meds are not the future for treating obesityMay 15, 2025 | seekingalpha.comZealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comZealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...May 9, 2025 | finance.yahoo.comInside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambitMay 2, 2025 | cnbc.comZealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?May 1, 2025 | zacks.comZealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetesApril 24, 2025 | reuters.comZealand Pharma appoints Utpal Singh as Chief Scientific OfficerApril 23, 2025 | contractpharma.comCZealand Pharma appoints Utpal Singh as CSOApril 23, 2025 | markets.businessinsider.comZealand Pharma Hires Lilly Executive as Biotech Ramps Up in ObesityApril 23, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRUU, ACBFF, MRUS, and ZLDPF Company DescriptionsAurora Cannabis OTCMKTS:ACBFF$5.05 +0.21 (+4.34%) As of 09/9/2025Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company's purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. The Company has a funded capacity of more than 500,000 kilograms per year, as well as sales and operations in more than 10 countries worldwide.Merus NASDAQ:MRUS$67.13 -1.42 (-2.07%) Closing price 04:00 PM EasternExtended Trading$67.15 +0.02 (+0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.True Drinks OTCMKTS:TRUU$0.31 +0.02 (+5.86%) As of 09/9/2025True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California.Zealand Pharma A/S OTCMKTS:ZLDPF$65.74 -5.75 (-8.04%) As of 02:13 PM EasternZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
